

TDMS No. 93025 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Tetralin

CAS Number: 119-64-2

Date Report Requested: 05/22/2008

Time Report Requested: 06:34:08

First Dose M/F: 06/23/03 / 06/23/03

Lab: BNW

C Number: C93025
Lock Date: 03/22/2006
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 2.0.0

TDMS No. 93025 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Tetralin

CAS Number: 119-64-2

Date Report Requested: 05/22/2008

Time Report Requested: 06:34:08

First Dose M/F: 06/23/03 / 06/23/03

Lab: BNW

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF Tetralin

MALE MICE

Organ

Adrenal Cortex

Heart: Artery

Intestine Small, Ileum

Lung: Alveolar Epithelium

Lymph Node, Mesenteric

Mesentery: Fat

Nose

Nose: Olfactory Epithelium

Nose: Olfactory Epithelium, Glands

Stomach, Forestomach

Stomach, Glandular

Urinary Bladder: Transitional Epithelium

Morphology

Atrophy

Hyperplasia

Hypertrophy

Inflammation Chronic

Infiltration Cellular Mixed Cell

Hyperplasia

Infiltration Cellular Mixed Cell

Infiltration Cellular Plasma Cell

Necrosis

Inflammation

Atrophy

Metaplasia Respiratory

Hyperplasia

Inflammation

Necrosis

Eosinophilic Granules Cytoplasmic

FEMALE MICE

Organ

Adrenal Cortex

Eye: Cornea

Heart

Islets, Pancreatic

Kidney

Liver

Lung: Alveolus

Mesentery: Fat

Nose

Nose: Olfactory Epithelium

Morphology

Hypertrophy

Mineralization

Cardiomyopathy

Hyperplasia

Metaplasia Osseous

Angiectasis

Basophilic Focus

Infiltration Cellular Histiocyte

Hemorrhage

Inflammation

Atrophy

Metaplasia Respiratory

TDMS No. 93025 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Tetralin

CAS Number: 119-64-2

Date Report Requested: 05/22/2008

Time Report Requested: 06:34:08

First Dose M/F: 06/23/03 / 06/23/03

Lab: BNW

SUMMARY OF STATISTICALLY SIGNIFICANT ($P \leq .05$) RESULTS IN THE ANALYSIS OF Tetralin

Nose: Olfactory Epithelium, Glands

Spleen

Urinary Bladder: Transitional Epithelium

Uterus: Endometrium

Hyperplasia

Hyperplasia Lymphoid

Eosinophilic Granules Cytoplasmic

Hyperplasia Cystic

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Adrenal Cortex
Atrophy**

LESION RATES

OVERALL (a)	2/49 (4%)	0/49 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/43.67	0/44.56	0/45.72	0/44.37
POLY-3 PERCENT (g)	4.6%	0%	0%	0%
TERMINAL (d)	2/36 (6%)	0/35 (0%)	0/38 (0%)	0/36 (0%)
FIRST INCIDENCE	729 (T)	---	---	---

STATISTICAL TESTS

POLY 3	P=0.112N	P=0.233N	P=0.227N	P=0.233N
POLY 1.5	P=0.112N	P=0.234N	P=0.229N	P=0.233N
POLY 6	P=0.112N	P=0.232N	P=0.225N	P=0.233N
COCH-ARM / FISHERS	P=0.113N	P=0.247N	P=0.242N	P=0.242N
MAX-ISO-POLY-3	P=0.032N*	P=0.076N	P=0.075N	P=0.075N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Adrenal Cortex
Hyperplasia**

LESION RATES

OVERALL (a)	17/49 (35%)	14/49 (29%)	10/50 (20%)	9/50 (18%)
POLY-3 RATE (b)	17/44.10	14/45.57	10/45.81	9/44.44
POLY-3 PERCENT (g)	38.6%	30.7%	21.8%	20.3%
TERMINAL (d)	16/36 (44%)	11/35 (31%)	9/38 (24%)	8/36 (22%)
FIRST INCIDENCE	604	454	707	712

STATISTICAL TESTS

POLY 3	P=0.030N*	P=0.288N	P=0.064N	P=0.046N*
POLY 1.5	P=0.029N*	P=0.302N	P=0.069N	P=0.046N*
POLY 6	P=0.029N*	P=0.280N	P=0.060N	P=0.045N*
COCH-ARM / FISHERS	P=0.029N*	P=0.332N	P=0.078N	P=0.048N*
MAX-ISO-POLY-3	P=0.041N*	P=0.221N	P=0.041N*	P=0.027N*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Adrenal Cortex
Hypertrophy**

LESION RATES

OVERALL (a)	24/49 (49%)	21/49 (43%)	16/50 (32%)	18/50 (36%)
POLY-3 RATE (b)	24/45.19	21/45.50	16/46.26	18/45.59
POLY-3 PERCENT (g)	53.1%	46.2%	34.6%	39.5%
TERMINAL (d)	19/36 (53%)	19/35 (54%)	14/38 (37%)	16/36 (44%)
FIRST INCIDENCE	516	576	607	498

STATISTICAL TESTS

POLY 3	P=0.096N	P=0.323N	P=0.054N	P=0.134N
POLY 1.5	P=0.096N	P=0.326N	P=0.056N	P=0.133N
POLY 6	P=0.096N	P=0.335N	P=0.053N	P=0.137N
COCH-ARM / FISHERS	P=0.097N	P=0.343N	P=0.064N	P=0.135N
MAX-ISO-POLY-3	P=0.091N	P=0.252N	P=0.035N*	P=0.093N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Adrenal Medulla
Hyperplasia**

LESION RATES

OVERALL (a)	1/47 (2%)	1/49 (2%)	0/49 (0%)	3/50 (6%)
POLY-3 RATE (b)	1/42.13	1/44.56	0/44.72	3/45.01
POLY-3 PERCENT (g)	2.4%	2.2%	0%	6.7%
TERMINAL (d)	0/34 (0%)	1/35 (3%)	0/37 (0%)	1/36 (3%)
FIRST INCIDENCE	593	729 (T)	---	563

STATISTICAL TESTS

POLY 3	P=0.171	P=0.748N	P=0.488N	P=0.329
POLY 1.5	P=0.171	P=0.749N	P=0.489N	P=0.328
POLY 6	P=0.172	P=0.749N	P=0.487N	P=0.331
COCH-ARM / FISHERS	P=0.171	P=0.742N	P=0.490N	P=0.332
MAX-ISO-POLY-3	P=0.123	P=0.484N	P=0.156N	P=0.175

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Epididymis
Granuloma Sperm**

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	1/44.69	0/45.07	0/45.72	2/44.37
POLY-3 PERCENT (g)	2.2%	0%	0%	4.5%
TERMINAL (d)	0/36 (0%)	0/35 (0%)	0/38 (0%)	2/36 (6%)
FIRST INCIDENCE	720	---	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.244	P=0.498N	P=0.495N	P=0.498
POLY 1.5	P=0.245	P=0.498N	P=0.497N	P=0.498
POLY 6	P=0.245	P=0.500N	P=0.494N	P=0.497
COCH-ARM / FISHERS	P=0.246	P=0.500N	P=0.500N	P=0.500
MAX-ISO-POLY-3	P=0.133	P=0.158N	P=0.158N	P=0.279

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Eye
Cataract**

LESION RATES

OVERALL (a)	1/48 (2%)	1/46 (2%)	1/47 (2%)	0/47 (0%)
POLY-3 RATE (b)	1/42.87	1/43.43	1/44.24	0/42.85
POLY-3 PERCENT (g)	2.3%	2.3%	2.3%	0%
TERMINAL (d)	1/36 (3%)	0/35 (0%)	0/38 (0%)	0/36 (0%)
FIRST INCIDENCE	729 (T)	602	707	---

STATISTICAL TESTS

POLY 3	P=0.313N	P=0.758N	P=0.754N	P=0.500N
POLY 1.5	P=0.314N	P=0.759	P=0.758N	P=0.502N
POLY 6	P=0.311N	P=0.754N	P=0.749N	P=0.498N
COCH-ARM / FISHERS	P=0.314N	P=0.742	P=0.747	P=0.505N
MAX-ISO-POLY-3	P=0.339N	P=0.495N	P=0.490N	P=0.160N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

Eye: Cornea
Inflammation Chronic

LESION RATES

OVERALL (a)	1/48 (2%)	3/46 (7%)	0/47 (0%)	0/47 (0%)
POLY-3 RATE (b)	1/42.87	3/43.00	0/44.16	0/42.85
POLY-3 PERCENT (g)	2.3%	7%	0%	0%
TERMINAL (d)	1/36 (3%)	3/35 (9%)	0/38 (0%)	0/36 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	---	---

STATISTICAL TESTS

POLY 3	P=0.146N	P=0.306	P=0.494N	P=0.500N
POLY 1.5	P=0.149N	P=0.301	P=0.498N	P=0.502N
POLY 6	P=0.143N	P=0.310	P=0.490N	P=0.498N
COCH-ARM / FISHERS	P=0.155N	P=0.292	P=0.505N	P=0.505N
MAX-ISO-POLY-3	P=0.121N	P=0.158	P=0.160N	P=0.160N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

Eye: Cornea
Mineralization

LESION RATES

OVERALL (a)	0/48 (0%)	0/46 (0%)	1/47 (2%)	2/47 (4%)
POLY-3 RATE (b)	0/42.87	0/43.00	1/44.16	2/42.85
POLY-3 PERCENT (g)	0%	0%	2.3%	4.7%
TERMINAL (d)	0/36 (0%)	0/35 (0%)	1/38 (3%)	2/36 (6%)
FIRST INCIDENCE	---	---	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.070	(e)	P=0.506	P=0.237
POLY 1.5	P=0.070	(e)	P=0.502	P=0.235
POLY 6	P=0.070	(e)	P=0.510	P=0.239
COCH-ARM / FISHERS	P=0.070	(e)	P=0.495	P=0.242
MAX-ISO-POLY-3	P=0.080	(e)	P=0.167	P=0.077

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Harderian Gland
Hyperplasia**

LESION RATES

OVERALL (a)	3/49 (6%)	1/47 (2%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	3/43.67	1/43.69	2/45.72	2/44.47
POLY-3 PERCENT (g)	6.9%	2.3%	4.4%	4.5%
TERMINAL (d)	3/36 (8%)	1/35 (3%)	2/38 (5%)	1/36 (3%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	705

STATISTICAL TESTS

POLY 3	P=0.493N	P=0.305N	P=0.479N	P=0.492N
POLY 1.5	P=0.490N	P=0.310N	P=0.483N	P=0.492N
POLY 6	P=0.493N	P=0.301N	P=0.475N	P=0.490N
COCH-ARM / FISHERS	P=0.484N	P=0.324N	P=0.490N	P=0.490N
MAX-ISO-POLY-3	P=0.393N	P=0.156N	P=0.308N	P=0.317N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Heart
Cardiomyopathy**

LESION RATES

OVERALL (a)	6/50 (12%)	2/50 (4%)	5/50 (10%)	5/50 (10%)
POLY-3 RATE (b)	6/44.94	2/45.30	5/46.15	5/44.63
POLY-3 PERCENT (g)	13.4%	4.4%	10.8%	11.2%
TERMINAL (d)	4/36 (11%)	1/35 (3%)	3/38 (8%)	3/36 (8%)
FIRST INCIDENCE	663	668	643	687

STATISTICAL TESTS

POLY 3	P=0.528	P=0.130N	P=0.481N	P=0.505N
POLY 1.5	P=0.529	P=0.131N	P=0.488N	P=0.503N
POLY 6	P=0.531	P=0.131N	P=0.474N	P=0.505N
COCH-ARM / FISHERS	P=0.533	P=0.134N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.387N	P=0.068N	P=0.358N	P=0.378N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Heart
Mineralization**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/44.65	1/45.11	0/45.72	2/44.54
POLY-3 PERCENT (g)	0%	2.2%	0%	4.5%
TERMINAL (d)	0/36 (0%)	0/35 (0%)	0/38 (0%)	1/36 (3%)
FIRST INCIDENCE	---	718	---	687

STATISTICAL TESTS

POLY 3	P=0.140	P=0.502	(e)	P=0.236
POLY 1.5	P=0.140	P=0.502	(e)	P=0.237
POLY 6	P=0.140	P=0.501	(e)	P=0.237
COCH-ARM / FISHERS	P=0.140	P=0.500	(e)	P=0.247
MAX-ISO-POLY-3	P=0.077	P=0.161	(e)	P=0.076

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Heart: Artery
Inflammation Chronic**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	0/44.65	0/45.07	3/46.36	0/44.37
POLY-3 PERCENT (g)	0%	0%	6.5%	0%
TERMINAL (d)	0/36 (0%)	0/35 (0%)	2/38 (5%)	0/36 (0%)
FIRST INCIDENCE	---	---	521	---

STATISTICAL TESTS

POLY 3	P=0.531	(e)	P=0.126	(e)
POLY 1.5	P=0.533	(e)	P=0.123	(e)
POLY 6	P=0.531	(e)	P=0.128	(e)
COCH-ARM / FISHERS	P=0.539	(e)	P=0.121	(e)
MAX-ISO-POLY-3	P=0.175	(e)	P=0.044*	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Intestine Small, Ileum
Infiltration Cellular Mixed Cell**

LESION RATES

OVERALL (a)	2/47 (4%)	0/44 (0%)	0/45 (0%)	0/47 (0%)
POLY-3 RATE (b)	2/43.13	0/41.64	0/42.56	0/42.85
POLY-3 PERCENT (g)	4.6%	0%	0%	0%
TERMINAL (d)	1/36 (3%)	0/35 (0%)	0/38 (0%)	0/36 (0%)
FIRST INCIDENCE	597	---	---	---

STATISTICAL TESTS

POLY 3	P=0.116N	P=0.245N	P=0.240N	P=0.238N
POLY 1.5	P=0.115N	P=0.247N	P=0.243N	P=0.238N
POLY 6	P=0.116N	P=0.243N	P=0.237N	P=0.239N
COCH-ARM / FISHERS	P=0.116N	P=0.264N	P=0.258N	P=0.247N
MAX-ISO-POLY-3	P=0.036N*	P=0.080N	P=0.078N	P=0.077N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Islets, Pancreatic
Hyperplasia**

LESION RATES

OVERALL (a)	2/49 (4%)	2/48 (4%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	2/43.71	2/43.93	3/45.72	0/44.37
POLY-3 PERCENT (g)	4.6%	4.6%	6.6%	0%
TERMINAL (d)	1/36 (3%)	2/35 (6%)	3/38 (8%)	0/36 (0%)
FIRST INCIDENCE	720	729 (T)	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.195N	P=0.692N	P=0.521	P=0.234N
POLY 1.5	P=0.194N	P=0.693	P=0.516	P=0.233N
POLY 6	P=0.195N	P=0.691N	P=0.525	P=0.233N
COCH-ARM / FISHERS	P=0.191N	P=0.684	P=0.510	P=0.242N
MAX-ISO-POLY-3	P=0.167N	P=0.497N	P=0.344	P=0.075N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Kidney
Infarct**

LESION RATES

OVERALL (a)	0/49 (0%)	2/49 (4%)	1/50 (2%)	0/49 (0%)
POLY-3 RATE (b)	0/43.67	2/44.56	1/46.18	0/44.06
POLY-3 PERCENT (g)	0%	4.5%	2.2%	0%
TERMINAL (d)	0/36 (0%)	2/35 (6%)	0/38 (0%)	0/36 (0%)
FIRST INCIDENCE	---	729 (T)	593	---

STATISTICAL TESTS

POLY 3	P=0.455N	P=0.242	P=0.511	(e)
POLY 1.5	P=0.457N	P=0.240	P=0.508	(e)
POLY 6	P=0.452N	P=0.241	P=0.514	(e)
COCH-ARM / FISHERS	P=0.460N	P=0.247	P=0.505	(e)
MAX-ISO-POLY-3	P=0.335N	P=0.080	P=0.171	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Kidney
Metaplasia Osseous**

LESION RATES

OVERALL (a)	0/49 (0%)	1/49 (2%)	2/50 (4%)	1/49 (2%)
POLY-3 RATE (b)	0/43.67	1/44.56	2/46.36	1/44.35
POLY-3 PERCENT (g)	0%	2.2%	4.3%	2.3%
TERMINAL (d)	0/36 (0%)	1/35 (3%)	1/38 (3%)	0/36 (0%)
FIRST INCIDENCE	---	729 (T)	521	649

STATISTICAL TESTS

POLY 3	P=0.373	P=0.504	P=0.251	P=0.503
POLY 1.5	P=0.370	P=0.503	P=0.247	P=0.502
POLY 6	P=0.378	P=0.504	P=0.254	P=0.505
COCH-ARM / FISHERS	P=0.367	P=0.500	P=0.253	P=0.500
MAX-ISO-POLY-3	P=0.244	P=0.164	P=0.088	P=0.162

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Kidney
Nephropathy**

LESION RATES

OVERALL (a)	46/49 (94%)	47/49 (96%)	48/50 (96%)	47/49 (96%)
POLY-3 RATE (b)	46/47.96	47/48.41	48/48.91	47/47.85
POLY-3 PERCENT (g)	95.9%	97.1%	98.1%	98.2%
TERMINAL (d)	35/36 (97%)	35/35 (100%)	38/38 (100%)	36/36 (100%)
FIRST INCIDENCE	422	454	493	444

STATISTICAL TESTS

POLY 3	P=0.310	P=0.607	P=0.476	P=0.469
POLY 1.5	P=0.364	P=0.562	P=0.483	P=0.482
POLY 6	P=0.248	P=0.653	P=0.468	P=0.462
COCH-ARM / FISHERS	P=0.430	P=0.500	P=0.490	P=0.500
MAX-ISO-POLY-3	P=0.317	P=0.360	P=0.218	P=0.210

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Kidney: Renal Tubule
Hyperplasia**

LESION RATES

OVERALL (a)	1/49 (2%)	4/49 (8%)	1/50 (2%)	4/49 (8%)
POLY-3 RATE (b)	1/43.67	4/44.56	1/45.72	4/44.06
POLY-3 PERCENT (g)	2.3%	9%	2.2%	9.1%
TERMINAL (d)	1/36 (3%)	4/35 (11%)	1/38 (3%)	4/36 (11%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.224	P=0.184	P=0.750N	P=0.181
POLY 1.5	P=0.223	P=0.183	P=0.752N	P=0.180
POLY 6	P=0.227	P=0.184	P=0.748N	P=0.182
COCH-ARM / FISHERS	P=0.221	P=0.181	P=0.747N	P=0.181
MAX-ISO-POLY-3	P=0.135	P=0.089	P=0.486N	P=0.086

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Liver
Angiectasis**

LESION RATES

OVERALL (a)	2/49 (4%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/44.88	1/45.07	0/45.72	0/44.37
POLY-3 PERCENT (g)	4.5%	2.2%	0%	0%
TERMINAL (d)	0/36 (0%)	1/35 (3%)	0/38 (0%)	0/36 (0%)
FIRST INCIDENCE	452	729 (T)	---	---

STATISTICAL TESTS

POLY 3	P=0.099N	P=0.499N	P=0.233N	P=0.240N
POLY 1.5	P=0.099N	P=0.495N	P=0.233N	P=0.237N
POLY 6	P=0.098N	P=0.504N	P=0.233N	P=0.242N
COCH-ARM / FISHERS	P=0.099N	P=0.492N	P=0.242N	P=0.242N
MAX-ISO-POLY-3	P=0.081N	P=0.280N	P=0.075N	P=0.079N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Liver
Basophilic Focus**

LESION RATES

OVERALL (a)	4/49 (8%)	4/50 (8%)	4/50 (8%)	1/50 (2%)
POLY-3 RATE (b)	4/43.67	4/45.44	4/45.72	1/44.37
POLY-3 PERCENT (g)	9.2%	8.8%	8.8%	2.3%
TERMINAL (d)	4/36 (11%)	3/35 (9%)	4/38 (11%)	1/36 (3%)
FIRST INCIDENCE	729 (T)	624	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.130N	P=0.621N	P=0.618N	P=0.173N
POLY 1.5	P=0.129N	P=0.624N	P=0.623N	P=0.173N
POLY 6	P=0.128N	P=0.621N	P=0.613N	P=0.173N
COCH-ARM / FISHERS	P=0.127N	P=0.631N	P=0.631N	P=0.175N
MAX-ISO-POLY-3	P=0.172N	P=0.476N	P=0.472N	P=0.081N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

Liver
Clear Cell Focus

LESION RATES

OVERALL (a)	16/49 (33%)	16/50 (32%)	14/50 (28%)	18/50 (36%)
POLY-3 RATE (b)	16/43.67	16/45.22	14/45.72	18/44.37
POLY-3 PERCENT (g)	36.6%	35.4%	30.6%	40.6%
TERMINAL (d)	16/36 (44%)	15/35 (43%)	14/38 (37%)	18/36 (50%)
FIRST INCIDENCE	729 (T)	690	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.389	P=0.539N	P=0.352N	P=0.436
POLY 1.5	P=0.393	P=0.543N	P=0.366N	P=0.439
POLY 6	P=0.392	P=0.543N	P=0.338N	P=0.437
COCH-ARM / FISHERS	P=0.401	P=0.558N	P=0.388N	P=0.445
MAX-ISO-POLY-3	P=0.428	P=0.450N	P=0.276N	P=0.351

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Liver
Eosinophilic Focus**

LESION RATES

OVERALL (a)	1/49 (2%)	1/50 (2%)	4/50 (8%)	3/50 (6%)
POLY-3 RATE (b)	1/43.71	1/45.07	4/45.72	3/44.76
POLY-3 PERCENT (g)	2.3%	2.2%	8.8%	6.7%
TERMINAL (d)	0/36 (0%)	1/35 (3%)	4/38 (11%)	1/36 (3%)
FIRST INCIDENCE	720	729 (T)	729 (T)	649

STATISTICAL TESTS

POLY 3	P=0.167	P=0.754N	P=0.192	P=0.314
POLY 1.5	P=0.167	P=0.754N	P=0.190	P=0.313
POLY 6	P=0.171	P=0.755N	P=0.195	P=0.316
COCH-ARM / FISHERS	P=0.168	P=0.747N	P=0.187	P=0.316
MAX-ISO-POLY-3	P=0.194	P=0.491N	P=0.096	P=0.162

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

Liver
Necrosis

LESION RATES

OVERALL (a)	2/49 (4%)	2/50 (4%)	0/50 (0%)	3/50 (6%)
POLY-3 RATE (b)	2/44.53	2/45.74	0/45.72	3/44.37
POLY-3 PERCENT (g)	4.5%	4.4%	0%	6.8%
TERMINAL (d)	0/36 (0%)	0/35 (0%)	0/38 (0%)	3/36 (8%)
FIRST INCIDENCE	592	602	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.422	P=0.684N	P=0.231N	P=0.498
POLY 1.5	P=0.425	P=0.684N	P=0.231N	P=0.503
POLY 6	P=0.420	P=0.687N	P=0.232N	P=0.493
COCH-ARM / FISHERS	P=0.429	P=0.684N	P=0.242N	P=0.510
MAX-ISO-POLY-3	P=0.289	P=0.488N	P=0.075N	P=0.323

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Liver
Tension Lipidosis**

LESION RATES

OVERALL (a)	2/49 (4%)	2/50 (4%)	3/50 (6%)	3/50 (6%)
POLY-3 RATE (b)	2/43.67	2/45.07	3/46.36	3/44.37
POLY-3 PERCENT (g)	4.6%	4.4%	6.5%	6.8%
TERMINAL (d)	2/36 (6%)	2/35 (6%)	2/38 (5%)	3/36 (8%)
FIRST INCIDENCE	729 (T)	729 (T)	521	729 (T)

STATISTICAL TESTS

POLY 3	P=0.376	P=0.683N	P=0.527	P=0.507
POLY 1.5	P=0.376	P=0.683N	P=0.520	P=0.508
POLY 6	P=0.378	P=0.685N	P=0.534	P=0.508
COCH-ARM / FISHERS	P=0.378	P=0.684N	P=0.510	P=0.510
MAX-ISO-POLY-3	P=0.518	P=0.487N	P=0.351	P=0.330

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Lung: Alveolar Epithelium
Hyperplasia**

LESION RATES

OVERALL (a)	2/50 (4%)	6/50 (12%)	8/50 (16%)	8/50 (16%)
POLY-3 RATE (b)	2/44.65	6/45.16	8/46.18	8/45.06
POLY-3 PERCENT (g)	4.5%	13.3%	17.3%	17.8%
TERMINAL (d)	2/36 (6%)	5/35 (14%)	7/38 (18%)	7/36 (19%)
FIRST INCIDENCE	729 (T)	705	593	498

STATISTICAL TESTS

POLY 3	P=0.053	P=0.136	P=0.051	P=0.046*
POLY 1.5	P=0.052	P=0.136	P=0.049*	P=0.046*
POLY 6	P=0.054	P=0.134	P=0.053	P=0.046*
COCH-ARM / FISHERS	P=0.053	P=0.134	P=0.046*	P=0.046*
MAX-ISO-POLY-3	P=0.049*	P=0.072	P=0.026*	P=0.022*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Lung: Alveolus
Infiltration Cellular Histiocyte**

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	1/45.12	0/45.07	2/46.14	1/44.37
POLY-3 PERCENT (g)	2.2%	0%	4.3%	2.3%
TERMINAL (d)	0/36 (0%)	0/35 (0%)	1/38 (3%)	1/36 (3%)
FIRST INCIDENCE	593	---	607	729 (T)

STATISTICAL TESTS

POLY 3	P=0.492	P=0.500N	P=0.508	P=0.757
POLY 1.5	P=0.495	P=0.499N	P=0.505	P=0.758
POLY 6	P=0.492	P=0.503N	P=0.511	P=0.756
COCH-ARM / FISHERS	P=0.500	P=0.500N	P=0.500	P=0.753N
MAX-ISO-POLY-3	P=0.393	P=0.159N	P=0.289	P=0.495

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Lung: Bronchiole
Hyperplasia**

LESION RATES

OVERALL (a)	4/50 (8%)	2/50 (4%)	1/50 (2%)	3/50 (6%)
POLY-3 RATE (b)	4/44.65	2/45.07	1/45.72	3/44.85
POLY-3 PERCENT (g)	9%	4.4%	2.2%	6.7%
TERMINAL (d)	4/36 (11%)	2/35 (6%)	1/38 (3%)	2/36 (6%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	586

STATISTICAL TESTS

POLY 3	P=0.455N	P=0.333N	P=0.171N	P=0.498N
POLY 1.5	P=0.456N	P=0.334N	P=0.174N	P=0.499N
POLY 6	P=0.451N	P=0.335N	P=0.168N	P=0.494N
COCH-ARM / FISHERS	P=0.456N	P=0.339N	P=0.181N	P=0.500N
MAX-ISO-POLY-3	P=0.284N	P=0.198N	P=0.082N	P=0.345N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Lymph Node, Mesenteric
Ectasia**

LESION RATES

OVERALL (a)	0/47 (0%)	0/48 (0%)	0/48 (0%)	0/48 (0%)
POLY-3 RATE (b)	0/43.08	0/43.87	0/44.12	0/42.44
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/35 (0%)	0/38 (0%)	0/35 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Lymph Node, Mesenteric
Infiltration Cellular Mixed Cell**

LESION RATES

OVERALL (a)	2/47 (4%)	0/48 (0%)	0/48 (0%)	0/48 (0%)
POLY-3 RATE (b)	2/43.53	0/43.87	0/44.12	0/42.44
POLY-3 PERCENT (g)	4.6%	0%	0%	0%
TERMINAL (d)	1/36 (3%)	0/35 (0%)	0/38 (0%)	0/35 (0%)
FIRST INCIDENCE	597	---	---	---

STATISTICAL TESTS

POLY 3	P=0.109N	P=0.235N	P=0.234N	P=0.243N
POLY 1.5	P=0.110N	P=0.234N	P=0.233N	P=0.239N
POLY 6	P=0.107N	P=0.239N	P=0.235N	P=0.247N
COCH-ARM / FISHERS	P=0.113N	P=0.242N	P=0.242N	P=0.242N
MAX-ISO-POLY-3	P=0.037N*	P=0.075N	P=0.075N	P=0.082N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Lymph Node, Mesenteric
Infiltration Cellular Plasma Cell**

LESION RATES

OVERALL (a)	2/47 (4%)	0/48 (0%)	0/48 (0%)	0/48 (0%)
POLY-3 RATE (b)	2/43.08	0/43.87	0/44.12	0/42.44
POLY-3 PERCENT (g)	4.6%	0%	0%	0%
TERMINAL (d)	2/36 (6%)	0/35 (0%)	0/38 (0%)	0/35 (0%)
FIRST INCIDENCE	729 (T)	---	---	---

STATISTICAL TESTS

POLY 3	P=0.110N	P=0.233N	P=0.232N	P=0.240N
POLY 1.5	P=0.111N	P=0.232N	P=0.232N	P=0.237N
POLY 6	P=0.108N	P=0.235N	P=0.231N	P=0.243N
COCH-ARM / FISHERS	P=0.113N	P=0.242N	P=0.242N	P=0.242N
MAX-ISO-POLY-3	P=0.035N*	P=0.075N	P=0.075N	P=0.080N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

Lymph Node: Lumbar
Ectasia

LESION RATES

OVERALL (a)	0/1 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
POLY-3 RATE (b)	0/1.00	0/0.00	0/0.00	0/0.00
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/1 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Lymph Node: Lumbar
Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	0/1 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
POLY-3 RATE (b)	0/1.00	0/0.00	0/0.00	0/0.00
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/1 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Lymph Node: Renal
Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	0/1 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
POLY-3 RATE (b)	0/1.00	0/0.00	0/0.00	0/0.00
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/1 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

Mesentery: Fat Hemorrhage

LESION RATES

OVERALL (a)	0/13 (0%)	0/4 (0%)	0/10 (0%)	0/2 (0%)
POLY-3 RATE (b)	0/12.96	0/3.86	0/9.58	0/2.00
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/12 (0%)	0/2 (0%)	0/9 (0%)	0/2 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Mesentery: Fat
Necrosis**

LESION RATES

OVERALL (a)	13/13 (100%)	4/4 (100%)	10/10 (100%)	1/2 (50%)
POLY-3 RATE (b)	13/13.00	4/4.00	10/10.00	1/2.00
POLY-3 PERCENT (g)	100%	100%	100%	50%
TERMINAL (d)	12/12 (100%)	2/2 (100%)	9/9 (100%)	1/2 (50%)
FIRST INCIDENCE	720	705	607	729 (T)

STATISTICAL TESTS

POLY 3	P=0.018N*	(e)	(e)	P=0.078N
POLY 1.5	P=0.018N*	(e)	(e)	P=0.078N
POLY 6	P=0.018N*	(e)	(e)	P=0.078N
COCH-ARM / FISHERS	P=0.052N	(e)	(e)	P=0.133N
MAX-ISO-POLY-3	P<0.001N**	(e)	(e)	P=0.005N**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Nose
Inflammation**

LESION RATES

OVERALL (a)	2/49 (4%)	26/49 (53%)	45/50 (90%)	46/50 (92%)
POLY-3 RATE (b)	2/44.06	26/45.21	45/47.63	46/49.05
POLY-3 PERCENT (g)	4.5%	57.5%	94.5%	93.8%
TERMINAL (d)	1/36 (3%)	23/35 (66%)	38/38 (100%)	34/36 (94%)
FIRST INCIDENCE	618	592	521	444

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Nose: Olfactory Epithelium
Atrophy**

LESION RATES

OVERALL (a)	2/49 (4%)	49/49 (100%)	50/50 (100%)	50/50 (100%)
POLY-3 RATE (b)	2/43.71	49/49.00	50/50.00	50/50.00
POLY-3 PERCENT (g)	4.6%	100%	100%	100%
TERMINAL (d)	1/36 (3%)	35/35 (100%)	38/38 (100%)	36/36 (100%)
FIRST INCIDENCE	720	454	493	444

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Nose: Olfactory Epithelium
Metaplasia Respiratory**

LESION RATES

OVERALL (a)	2/49 (4%)	47/49 (96%)	50/50 (100%)	49/50 (98%)
POLY-3 RATE (b)	2/43.67	47/47.81	50/50.00	49/49.71
POLY-3 PERCENT (g)	4.6%	98.3%	100%	98.6%
TERMINAL (d)	2/36 (6%)	35/35 (100%)	38/38 (100%)	36/36 (100%)
FIRST INCIDENCE	729 (T)	576	493	444

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Nose: Olfactory Epithelium, Glands
Hyperplasia**

LESION RATES

OVERALL (a)	14/49 (29%)	49/49 (100%)	50/50 (100%)	49/50 (98%)
POLY-3 RATE (b)	14/44.41	49/49.00	50/50.00	49/50.00
POLY-3 PERCENT (g)	31.5%	100%	100%	98%
TERMINAL (d)	11/36 (31%)	35/35 (100%)	38/38 (100%)	35/36 (97%)
FIRST INCIDENCE	597	454	493	444

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Pituitary Gland: Pars Distalis
Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	1/49 (2%)	0/48 (0%)	0/49 (0%)
POLY-3 RATE (b)	0/44.65	1/44.56	0/45.04	0/43.37
POLY-3 PERCENT (g)	0%	2.2%	0%	0%
TERMINAL (d)	0/36 (0%)	1/35 (3%)	0/38 (0%)	0/35 (0%)
FIRST INCIDENCE	---	729 (T)	---	---

STATISTICAL TESTS

POLY 3	P=0.564N	P=0.500	(e)	(e)
POLY 1.5	P=0.566N	P=0.499	(e)	(e)
POLY 6	P=0.563N	P=0.499	(e)	(e)
COCH-ARM / FISHERS	P=0.570N	P=0.495	(e)	(e)
MAX-ISO-POLY-3	P=0.397N	P=0.159	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Skin
Inflammation Chronic**

LESION RATES

OVERALL (a)	3/50 (6%)	4/49 (8%)	7/50 (14%)	6/50 (12%)
POLY-3 RATE (b)	3/45.51	4/44.22	7/47.23	6/45.34
POLY-3 PERCENT (g)	6.6%	9.1%	14.8%	13.2%
TERMINAL (d)	1/36 (3%)	3/34 (9%)	3/38 (8%)	2/36 (6%)
FIRST INCIDENCE	452	690	521	586

STATISTICAL TESTS

POLY 3	P=0.173	P=0.484	P=0.173	P=0.240
POLY 1.5	P=0.171	P=0.487	P=0.167	P=0.240
POLY 6	P=0.180	P=0.478	P=0.181	P=0.244
COCH-ARM / FISHERS	P=0.173	P=0.489	P=0.159	P=0.243
MAX-ISO-POLY-3	P=0.209	P=0.334	P=0.104	P=0.145

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Spleen
Hematopoietic Cell Proliferation**

LESION RATES

OVERALL (a)	5/49 (10%)	5/49 (10%)	2/49 (4%)	5/49 (10%)
POLY-3 RATE (b)	5/45.78	5/45.66	2/45.68	5/45.81
POLY-3 PERCENT (g)	10.9%	11%	4.4%	10.9%
TERMINAL (d)	1/36 (3%)	1/35 (3%)	1/38 (3%)	1/36 (3%)
FIRST INCIDENCE	452	592	656	498

STATISTICAL TESTS

POLY 3	P=0.517N	P=0.629	P=0.217N	P=0.630N
POLY 1.5	P=0.517N	P=0.630N	P=0.216N	P=0.630N
POLY 6	P=0.515N	P=0.624	P=0.219N	P=0.629N
COCH-ARM / FISHERS	P=0.517N	P=0.630N	P=0.218N	P=0.630N
MAX-ISO-POLY-3	P=0.472N	P=0.497	P=0.120N	P=0.499N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Spleen
Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	0/49 (0%)	1/49 (2%)	0/49 (0%)	0/49 (0%)
POLY-3 RATE (b)	0/43.67	1/44.56	0/45.41	0/44.09
POLY-3 PERCENT (g)	0%	2.2%	0%	0%
TERMINAL (d)	0/36 (0%)	1/35 (3%)	0/38 (0%)	0/36 (0%)
FIRST INCIDENCE	---	729 (T)	---	---

STATISTICAL TESTS

POLY 3	P=0.562N	P=0.504	(e)	(e)
POLY 1.5	P=0.564N	P=0.503	(e)	(e)
POLY 6	P=0.561N	P=0.504	(e)	(e)
COCH-ARM / FISHERS	P=0.567N	P=0.500	(e)	(e)
MAX-ISO-POLY-3	P=0.391N	P=0.164	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Stomach, Forestomach
Hyperplasia**

LESION RATES

OVERALL (a)	1/49 (2%)	1/48 (2%)	4/50 (8%)	4/50 (8%)
POLY-3 RATE (b)	1/44.13	1/43.93	4/46.77	4/44.37
POLY-3 PERCENT (g)	2.3%	2.3%	8.6%	9%
TERMINAL (d)	0/36 (0%)	1/35 (3%)	2/38 (5%)	4/36 (11%)
FIRST INCIDENCE	593	729 (T)	523	729 (T)

STATISTICAL TESTS

POLY 3	P=0.078	P=0.760	P=0.197	P=0.180
POLY 1.5	P=0.080	P=0.759	P=0.193	P=0.182
POLY 6	P=0.076	P=0.759	P=0.201	P=0.178
COCH-ARM / FISHERS	P=0.083	P=0.747	P=0.187	P=0.187
MAX-ISO-POLY-3	P=0.122	P=0.498	P=0.100	P=0.085

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Stomach, Forestomach
Inflammation**

LESION RATES

OVERALL (a)	0/49 (0%)	1/48 (2%)	4/50 (8%)	3/50 (6%)
POLY-3 RATE (b)	0/43.67	1/43.93	4/46.23	3/44.37
POLY-3 PERCENT (g)	0%	2.3%	8.7%	6.8%
TERMINAL (d)	0/36 (0%)	1/35 (3%)	2/38 (5%)	3/36 (8%)
FIRST INCIDENCE	---	729 (T)	593	729 (T)

STATISTICAL TESTS

POLY 3	P=0.073	P=0.501	P=0.068	P=0.121
POLY 1.5	P=0.074	P=0.499	P=0.066	P=0.122
POLY 6	P=0.072	P=0.502	P=0.070	P=0.121
COCH-ARM / FISHERS	P=0.077	P=0.495	P=0.061	P=0.125
MAX-ISO-POLY-3	P=0.064	P=0.161	P=0.025*	P=0.039*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Stomach, Forestomach
Ulcer**

LESION RATES

OVERALL (a)	1/49 (2%)	0/48 (0%)	3/50 (6%)	3/50 (6%)
POLY-3 RATE (b)	1/43.87	0/43.93	3/46.46	3/45.16
POLY-3 PERCENT (g)	2.3%	0%	6.5%	6.6%
TERMINAL (d)	0/36 (0%)	0/35 (0%)	1/38 (3%)	1/36 (3%)
FIRST INCIDENCE	677	---	607	478

STATISTICAL TESTS

POLY 3	P=0.114	P=0.500N	P=0.326	P=0.316
POLY 1.5	P=0.114	P=0.501N	P=0.321	P=0.315
POLY 6	P=0.115	P=0.500N	P=0.332	P=0.317
COCH-ARM / FISHERS	P=0.115	P=0.505N	P=0.316	P=0.316
MAX-ISO-POLY-3	P=0.148	P=0.160N	P=0.174	P=0.164

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Stomach, Glandular
Necrosis**

LESION RATES

OVERALL (a)	3/49 (6%)	2/47 (4%)	0/48 (0%)	0/48 (0%)
POLY-3 RATE (b)	3/45.55	2/43.97	0/43.92	0/43.13
POLY-3 PERCENT (g)	6.6%	4.6%	0%	0%
TERMINAL (d)	0/36 (0%)	0/35 (0%)	0/38 (0%)	0/36 (0%)
FIRST INCIDENCE	422	668	---	---

STATISTICAL TESTS

POLY 3	P=0.041N*	P=0.516N	P=0.125N	P=0.129N
POLY 1.5	P=0.040N*	P=0.517N	P=0.124N	P=0.126N
POLY 6	P=0.041N*	P=0.517N	P=0.126N	P=0.130N
COCH-ARM / FISHERS	P=0.040N*	P=0.520N	P=0.125N	P=0.125N
MAX-ISO-POLY-3	P=0.052N	P=0.339N	P=0.042N*	P=0.046N*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Testes
Atrophy**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/44.65	0/45.07	2/45.77	0/44.37
POLY-3 PERCENT (g)	0%	0%	4.4%	0%
TERMINAL (d)	0/36 (0%)	0/35 (0%)	1/38 (3%)	0/36 (0%)
FIRST INCIDENCE	---	---	716	---

STATISTICAL TESTS

POLY 3	P=0.589	(e)	P=0.243	(e)
POLY 1.5	P=0.591	(e)	P=0.241	(e)
POLY 6	P=0.589	(e)	P=0.245	(e)
COCH-ARM / FISHERS	P=0.595	(e)	P=0.247	(e)
MAX-ISO-POLY-3	P=0.257	(e)	P=0.081	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

Tooth Malformation

LESION RATES

OVERALL (a)	6/7 (86%)	6/6 (100%)	7/7 (100%)	1/1 (100%)
POLY-3 RATE (b)	6/6.61	6/6.00	7/7.00	1/1.00
POLY-3 PERCENT (g)	90.8%	100%	100%	100%
TERMINAL (d)	4/4 (100%)	5/5 (100%)	7/7 (100%)	1/1 (100%)
FIRST INCIDENCE	604	705	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.688	P=0.747	P=0.724	P=0.968
POLY 1.5	P=0.556	P=0.631	P=0.603	P=0.921
POLY 6	P=0.934	P=0.949	P=0.942	P=0.999
COCH-ARM / FISHERS	P=0.444	P=0.538	P=0.500	P=0.875
MAX-ISO-POLY-3	P=0.510	P=0.181	P=0.166	P=0.392

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Urinary Bladder: Transitional Epithelium
Eosinophilic Granules Cytoplasmic**

LESION RATES

OVERALL (a)	0/49 (0%)	47/47 (100%)	50/50 (100%)	48/48 (100%)
POLY-3 RATE (b)	0/43.67	47/47.00	50/50.00	48/48.00
POLY-3 PERCENT (g)	0%	100%	100%	100%
TERMINAL (d)	0/36 (0%)	35/35 (100%)	38/38 (100%)	36/36 (100%)
FIRST INCIDENCE	---	576	493	444

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Adrenal Cortex
Atrophy**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/40.70	0/45.29	0/48.78	0/48.62
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/42 (0%)	0/43 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Adrenal Cortex
Hyperplasia**

LESION RATES

OVERALL (a)	5/50 (10%)	3/50 (6%)	12/50 (24%)	5/50 (10%)
POLY-3 RATE (b)	5/41.70	3/45.29	12/48.78	5/48.66
POLY-3 PERCENT (g)	12%	6.6%	24.6%	10.3%
TERMINAL (d)	4/31 (13%)	3/38 (8%)	12/42 (29%)	4/43 (9%)
FIRST INCIDENCE	124	731 (T)	731 (T)	721

STATISTICAL TESTS

POLY 3	P=0.508	P=0.312N	P=0.103	P=0.530N
POLY 1.5	P=0.456	P=0.330N	P=0.081	P=0.569N
POLY 6	P=0.564	P=0.290N	P=0.131	P=0.487N
COCH-ARM / FISHERS	P=0.372	P=0.357N	P=0.054	P=0.630N
MAX-ISO-POLY-3	P=0.233	P=0.205N	P=0.077	P=0.404N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Adrenal Cortex
Hypertrophy**

LESION RATES

OVERALL (a)	5/50 (10%)	1/50 (2%)	2/50 (4%)	3/50 (6%)
POLY-3 RATE (b)	5/41.17	1/45.29	2/48.78	3/48.65
POLY-3 PERCENT (g)	12.1%	2.2%	4.1%	6.2%
TERMINAL (d)	4/31 (13%)	1/38 (3%)	2/42 (5%)	2/43 (5%)
FIRST INCIDENCE	592	731 (T)	731 (T)	723

STATISTICAL TESTS

POLY 3	P=0.364N	P=0.081N	P=0.154N	P=0.270N
POLY 1.5	P=0.374N	P=0.088N	P=0.174N	P=0.299N
POLY 6	P=0.356N	P=0.074N	P=0.136N	P=0.241N
COCH-ARM / FISHERS	P=0.397N	P=0.102N	P=0.218N	P=0.357N
MAX-ISO-POLY-3	P=0.118N	P=0.040N*	P=0.096N	P=0.182N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Adrenal Medulla
Hyperplasia**

LESION RATES

OVERALL (a)	2/50 (4%)	2/50 (4%)	1/50 (2%)	5/50 (10%)
POLY-3 RATE (b)	2/40.92	2/45.29	1/48.78	5/48.70
POLY-3 PERCENT (g)	4.9%	4.4%	2.1%	10.3%
TERMINAL (d)	1/31 (3%)	2/38 (5%)	1/42 (2%)	3/43 (7%)
FIRST INCIDENCE	674	731 (T)	731 (T)	721

STATISTICAL TESTS

POLY 3	P=0.144	P=0.657N	P=0.439N	P=0.293
POLY 1.5	P=0.134	P=0.670N	P=0.460N	P=0.265
POLY 6	P=0.155	P=0.643N	P=0.419N	P=0.324
COCH-ARM / FISHERS	P=0.114	P=0.691N	P=0.500N	P=0.218
MAX-ISO-POLY-3	P=0.172	P=0.460N	P=0.249N	P=0.194

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Eye
Cataract**

LESION RATES

OVERALL (a)	2/49 (4%)	1/49 (2%)	1/49 (2%)	0/49 (0%)
POLY-3 RATE (b)	2/41.07	1/44.33	1/48.17	0/47.80
POLY-3 PERCENT (g)	4.9%	2.3%	2.1%	0%
TERMINAL (d)	1/31 (3%)	1/38 (3%)	0/42 (0%)	0/43 (0%)
FIRST INCIDENCE	432	731 (T)	704	---

STATISTICAL TESTS

POLY 3	P=0.137N	P=0.473N	P=0.445N	P=0.205N
POLY 1.5	P=0.143N	P=0.483N	P=0.464N	P=0.216N
POLY 6	P=0.132N	P=0.463N	P=0.425N	P=0.194N
COCH-ARM / FISHERS	P=0.153N	P=0.500N	P=0.500N	P=0.247N
MAX-ISO-POLY-3	P=0.121N	P=0.266N	P=0.252N	P=0.076N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

Eye: Cornea
Inflammation Chronic

LESION RATES

OVERALL (a)	0/49 (0%)	0/49 (0%)	0/49 (0%)	1/49 (2%)
POLY-3 RATE (b)	0/40.28	0/44.33	0/48.07	1/47.80
POLY-3 PERCENT (g)	0%	0%	0%	2.1%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/42 (0%)	1/43 (2%)
FIRST INCIDENCE	---	---	---	731 (T)

STATISTICAL TESTS

POLY 3	P=0.218	(e)	(e)	P=0.534
POLY 1.5	P=0.211	(e)	(e)	P=0.522
POLY 6	P=0.226	(e)	(e)	P=0.546
COCH-ARM / FISHERS	P=0.198	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.185	(e)	(e)	P=0.200

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Eye: Cornea
Mineralization**

LESION RATES

OVERALL (a)	0/49 (0%)	3/49 (6%)	3/49 (6%)	12/49 (24%)
POLY-3 RATE (b)	0/40.28	3/44.33	3/48.13	12/47.80
POLY-3 PERCENT (g)	0%	6.8%	6.2%	25.1%
TERMINAL (d)	0/31 (0%)	3/38 (8%)	2/42 (5%)	12/43 (28%)
FIRST INCIDENCE	---	731 (T)	714	731 (T)

STATISTICAL TESTS

POLY 3	P<0.001**	P=0.137	P=0.154	P<0.001**
POLY 1.5	P<0.001**	P=0.130	P=0.141	P<0.001**
POLY 6	P<0.001**	P=0.144	P=0.169	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.121	P=0.121	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.053	P=0.069	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Harderian Gland
Hyperplasia**

LESION RATES

OVERALL (a)	2/50 (4%)	2/50 (4%)	4/49 (8%)	2/49 (4%)
POLY-3 RATE (b)	2/40.70	2/45.73	4/48.21	2/47.80
POLY-3 PERCENT (g)	4.9%	4.4%	8.3%	4.2%
TERMINAL (d)	2/31 (7%)	0/38 (0%)	3/42 (7%)	2/43 (5%)
FIRST INCIDENCE	731 (T)	639	690	731 (T)

STATISTICAL TESTS

POLY 3	P=0.558N	P=0.651N	P=0.418	P=0.634N
POLY 1.5	P=0.586N	P=0.667N	P=0.386	P=0.658N
POLY 6	P=0.530N	P=0.632N	P=0.453	P=0.607N
COCH-ARM / FISHERS	P=0.533	P=0.691N	P=0.329	P=0.684
MAX-ISO-POLY-3	P=0.585N	P=0.454N	P=0.283	P=0.439N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Heart
Cardiomyopathy**

LESION RATES

OVERALL (a)	6/50 (12%)	5/50 (10%)	1/50 (2%)	4/50 (8%)
POLY-3 RATE (b)	6/40.92	5/46.61	1/48.78	4/48.73
POLY-3 PERCENT (g)	14.7%	10.7%	2.1%	8.2%
TERMINAL (d)	5/31 (16%)	3/38 (8%)	1/42 (2%)	3/43 (7%)
FIRST INCIDENCE	673	401	731 (T)	705

STATISTICAL TESTS

POLY 3	P=0.196N	P=0.410N	P=0.033N*	P=0.266N
POLY 1.5	P=0.209N	P=0.441N	P=0.040N*	P=0.301N
POLY 6	P=0.184N	P=0.377N	P=0.027N*	P=0.233N
COCH-ARM / FISHERS	P=0.240N	P=0.500N	P=0.056N	P=0.370N
MAX-ISO-POLY-3	P=0.116N	P=0.303N	P=0.020N*	P=0.188N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Heart
Mineralization**

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	1/41.70	0/45.29	1/48.85	1/48.66
POLY-3 PERCENT (g)	2.4%	0%	2.1%	2.1%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/42 (0%)	0/43 (0%)
FIRST INCIDENCE	124	---	714	721

STATISTICAL TESTS

POLY 3	P=0.574	P=0.484N	P=0.724N	P=0.725N
POLY 1.5	P=0.561	P=0.490N	P=0.738N	P=0.739N
POLY 6	P=0.587	P=0.476N	P=0.708N	P=0.709N
COCH-ARM / FISHERS	P=0.539	P=0.500N	P=0.753N	P=0.753N
MAX-ISO-POLY-3	P=0.577N	P=0.158N	P=0.458N	P=0.458N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Heart: Artery
Inflammation Chronic**

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/40.70	0/45.29	1/48.78	0/48.62
POLY-3 PERCENT (g)	2.5%	0%	2.1%	0%
TERMINAL (d)	1/31 (3%)	0/38 (0%)	1/42 (2%)	0/43 (0%)
FIRST INCIDENCE	731 (T)	---	731 (T)	---

STATISTICAL TESTS

POLY 3	P=0.392N	P=0.479N	P=0.718N	P=0.465N
POLY 1.5	P=0.396N	P=0.486N	P=0.733N	P=0.477N
POLY 6	P=0.389N	P=0.470N	P=0.702N	P=0.452N
COCH-ARM / FISHERS	P=0.405N	P=0.500N	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.255N	P=0.158N	P=0.452N	P=0.158N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Intestine Small, Ileum
Infiltration Cellular Mixed Cell**

LESION RATES

OVERALL (a)	0/48 (0%)	0/48 (0%)	0/49 (0%)	0/49 (0%)
POLY-3 RATE (b)	0/40.15	0/43.43	0/48.07	0/47.80
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/42 (0%)	0/43 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Islets, Pancreatic
Hyperplasia**

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/40.70	0/45.29	0/48.78	0/48.62
POLY-3 PERCENT (g)	4.9%	0%	0%	0%
TERMINAL (d)	2/31 (7%)	0/38 (0%)	0/42 (0%)	0/43 (0%)
FIRST INCIDENCE	731 (T)	---	---	---

STATISTICAL TESTS

POLY 3	P=0.125N	P=0.214N	P=0.200N	P=0.200N
POLY 1.5	P=0.120N	P=0.222N	P=0.212N	P=0.213N
POLY 6	P=0.132N	P=0.205N	P=0.187N	P=0.188N
COCH-ARM / FISHERS	P=0.115N	P=0.247N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.032N*	P=0.075N	P=0.075N	P=0.075N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Kidney
Infarct**

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/40.94	1/45.77	0/48.78	0/48.62
POLY-3 PERCENT (g)	2.4%	2.2%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/42 (0%)	0/43 (0%)
FIRST INCIDENCE	666	586	---	---

STATISTICAL TESTS

POLY 3	P=0.226N	P=0.735N	P=0.465N	P=0.466N
POLY 1.5	P=0.229N	P=0.744N	P=0.477N	P=0.478N
POLY 6	P=0.224N	P=0.725N	P=0.454N	P=0.454N
COCH-ARM / FISHERS	P=0.236N	P=0.753N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.255N	P=0.469N	P=0.158N	P=0.158N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Kidney
Metaplasia Osseous**

LESION RATES

OVERALL (a)	0/50 (0%)	3/50 (6%)	4/50 (8%)	2/50 (4%)
POLY-3 RATE (b)	0/40.70	3/45.83	4/48.78	2/48.62
POLY-3 PERCENT (g)	0%	6.6%	8.2%	4.1%
TERMINAL (d)	0/31 (0%)	2/38 (5%)	4/42 (10%)	2/43 (5%)
FIRST INCIDENCE	---	563	731 (T)	731 (T)

STATISTICAL TESTS

POLY 3	P=0.414	P=0.141	P=0.088	P=0.279
POLY 1.5	P=0.373	P=0.133	P=0.077	P=0.264
POLY 6	P=0.457	P=0.152	P=0.099	P=0.296
COCH-ARM / FISHERS	P=0.302	P=0.121	P=0.059	P=0.247
MAX-ISO-POLY-3	P=0.172	P=0.057	P=0.042*	P=0.116

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Kidney
Nephropathy**

LESION RATES

OVERALL (a)	40/50 (80%)	40/50 (80%)	43/50 (86%)	38/50 (76%)
POLY-3 RATE (b)	40/45.35	40/47.77	43/49.56	38/49.48
POLY-3 PERCENT (g)	88.2%	83.7%	86.8%	76.8%
TERMINAL (d)	28/31 (90%)	32/38 (84%)	37/42 (88%)	34/43 (79%)
FIRST INCIDENCE	394	401	653	530

STATISTICAL TESTS

POLY 3	P=0.087N	P=0.366N	P=0.540N	P=0.109N
POLY 1.5	P=0.147N	P=0.438N	P=0.580	P=0.177N
POLY 6	P=0.054N	P=0.308N	P=0.435N	P=0.069N
COCH-ARM / FISHERS	P=0.370N	P=0.598N	P=0.298	P=0.405N
MAX-ISO-POLY-3	P=0.108N	P=0.261N	P=0.413N	P=0.073N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Kidney: Renal Tubule
Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/40.70	0/45.29	0/48.78	0/48.62
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/42 (0%)	0/43 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 93025 - 06
 Test Type: CHRONIC
 Route: RESPIRATORY EXPOSURE WHOLE BODY
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Tetralin
 CAS Number: 119-64-2

Date Report Requested: 05/22/2008
 Time Report Requested: 06:34:08
 First Dose M/F: 06/23/03 / 06/23/03
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Liver
 Angiectasis**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/40.70	0/45.29	0/48.78	2/48.62
POLY-3 PERCENT (g)	0%	0%	0%	4.1%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/42 (0%)	2/43 (5%)
FIRST INCIDENCE	---	---	---	731 (T)

STATISTICAL TESTS

POLY 3	P=0.052	(e)	(e)	P=0.279
POLY 1.5	P=0.050*	(e)	(e)	P=0.264
POLY 6	P=0.054	(e)	(e)	P=0.296
COCH-ARM / FISHERS	P=0.046*	(e)	(e)	P=0.247
MAX-ISO-POLY-3	P=0.070	(e)	(e)	P=0.116

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Liver
Basophilic Focus**

LESION RATES

OVERALL (a)	3/50 (6%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	3/41.43	0/45.29	0/48.78	1/48.62
POLY-3 PERCENT (g)	7.2%	0%	0%	2.1%
TERMINAL (d)	1/31 (3%)	0/38 (0%)	0/42 (0%)	1/43 (2%)
FIRST INCIDENCE	514	---	---	731 (T)

STATISTICAL TESTS

POLY 3	P=0.255N	P=0.103N	P=0.092N	P=0.251N
POLY 1.5	P=0.251N	P=0.109N	P=0.101N	P=0.269N
POLY 6	P=0.261N	P=0.098N	P=0.085N	P=0.233N
COCH-ARM / FISHERS	P=0.247N	P=0.121N	P=0.121N	P=0.309N
MAX-ISO-POLY-3	P=0.039N*	P=0.038N*	P=0.038N*	P=0.136N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

Liver
Clear Cell Focus

LESION RATES

OVERALL (a)	2/50 (4%)	2/50 (4%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	2/41.28	2/45.29	2/48.78	2/48.62
POLY-3 PERCENT (g)	4.9%	4.4%	4.1%	4.1%
TERMINAL (d)	1/31 (3%)	2/38 (5%)	2/42 (5%)	2/43 (5%)
FIRST INCIDENCE	549	731 (T)	731 (T)	731 (T)

STATISTICAL TESTS

POLY 3	P=0.540N	P=0.660N	P=0.632N	P=0.633N
POLY 1.5	P=0.558N	P=0.672N	P=0.653N	P=0.654N
POLY 6	P=0.522N	P=0.647N	P=0.610N	P=0.610N
COCH-ARM / FISHERS	P=0.596	P=0.691N	P=0.691N	P=0.691N
MAX-ISO-POLY-3	P=0.674N	P=0.463N	P=0.436N	P=0.437N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Liver
Eosinophilic Focus**

LESION RATES

OVERALL (a)	3/50 (6%)	2/50 (4%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	3/40.94	2/45.29	1/48.78	1/48.62
POLY-3 PERCENT (g)	7.3%	4.4%	2.1%	2.1%
TERMINAL (d)	2/31 (7%)	2/38 (5%)	1/42 (2%)	1/43 (2%)
FIRST INCIDENCE	666	731 (T)	731 (T)	731 (T)

STATISTICAL TESTS

POLY 3	P=0.173N	P=0.454N	P=0.246N	P=0.247N
POLY 1.5	P=0.181N	P=0.470N	P=0.266N	P=0.267N
POLY 6	P=0.165N	P=0.437N	P=0.228N	P=0.228N
COCH-ARM / FISHERS	P=0.199N	P=0.500N	P=0.309N	P=0.309N
MAX-ISO-POLY-3	P=0.192N	P=0.293N	P=0.135N	P=0.135N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

Liver
Necrosis

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	2/40.94	0/45.29	0/48.78	2/48.66
POLY-3 PERCENT (g)	4.9%	0%	0%	4.1%
TERMINAL (d)	1/31 (3%)	0/38 (0%)	0/42 (0%)	1/43 (2%)
FIRST INCIDENCE	666	---	---	721

STATISTICAL TESTS

POLY 3	P=0.511	P=0.215N	P=0.201N	P=0.630N
POLY 1.5	P=0.508	P=0.223N	P=0.213N	P=0.652N
POLY 6	P=0.513	P=0.208N	P=0.190N	P=0.605N
COCH-ARM / FISHERS	P=0.500	P=0.247N	P=0.247N	P=0.691N
MAX-ISO-POLY-3	P=0.247N	P=0.076N	P=0.075N	P=0.434N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Liver
Tension Lipidosis**

LESION RATES

OVERALL (a)	3/50 (6%)	8/50 (16%)	3/50 (6%)	3/50 (6%)
POLY-3 RATE (b)	3/41.59	8/45.60	3/49.06	3/48.62
POLY-3 PERCENT (g)	7.2%	17.5%	6.1%	6.2%
TERMINAL (d)	1/31 (3%)	7/38 (18%)	2/42 (5%)	3/43 (7%)
FIRST INCIDENCE	519	645	656	731 (T)

STATISTICAL TESTS

POLY 3	P=0.225N	P=0.129	P=0.584N	P=0.588N
POLY 1.5	P=0.254N	P=0.118	P=0.611N	P=0.613N
POLY 6	P=0.199N	P=0.142	P=0.556N	P=0.561N
COCH-ARM / FISHERS	P=0.319N	P=0.100	P=0.661N	P=0.661N
MAX-ISO-POLY-3	P=0.266N	P=0.082	P=0.422N	P=0.426N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Lung: Alveolar Epithelium
Hyperplasia**

LESION RATES

OVERALL (a)	4/50 (8%)	6/50 (12%)	3/50 (6%)	6/50 (12%)
POLY-3 RATE (b)	4/40.70	6/45.45	3/48.78	6/48.62
POLY-3 PERCENT (g)	9.8%	13.2%	6.2%	12.3%
TERMINAL (d)	4/31 (13%)	5/38 (13%)	3/42 (7%)	6/43 (14%)
FIRST INCIDENCE	731 (T)	690	731 (T)	731 (T)

STATISTICAL TESTS

POLY 3	P=0.495	P=0.440	P=0.403N	P=0.485
POLY 1.5	P=0.459	P=0.415	P=0.436N	P=0.444
POLY 6	P=0.531	P=0.471	P=0.369N	P=0.529
COCH-ARM / FISHERS	P=0.388	P=0.370	P=0.500N	P=0.370
MAX-ISO-POLY-3	P=0.558	P=0.322	P=0.279N	P=0.365

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Lung: Alveolus
Infiltration Cellular Histiocyte**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/40.70	0/45.29	0/48.78	2/48.62
POLY-3 PERCENT (g)	0%	0%	0%	4.1%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/42 (0%)	2/43 (5%)
FIRST INCIDENCE	---	---	---	731 (T)

STATISTICAL TESTS

POLY 3	P=0.052	(e)	(e)	P=0.279
POLY 1.5	P=0.050*	(e)	(e)	P=0.264
POLY 6	P=0.054	(e)	(e)	P=0.296
COCH-ARM / FISHERS	P=0.046*	(e)	(e)	P=0.247
MAX-ISO-POLY-3	P=0.070	(e)	(e)	P=0.116

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Lung: Bronchiole
Hyperplasia**

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	1/40.70	1/45.29	0/48.78	1/48.62
POLY-3 PERCENT (g)	2.5%	2.2%	0%	2.1%
TERMINAL (d)	1/31 (3%)	1/38 (3%)	0/42 (0%)	1/43 (2%)
FIRST INCIDENCE	731 (T)	731 (T)	---	731 (T)

STATISTICAL TESTS

POLY 3	P=0.599N	P=0.736N	P=0.464N	P=0.719N
POLY 1.5	P=0.604N	P=0.745N	P=0.476N	P=0.734N
POLY 6	P=0.596N	P=0.726N	P=0.452N	P=0.703N
COCH-ARM / FISHERS	P=0.616N	P=0.753N	P=0.500N	P=0.753N
MAX-ISO-POLY-3	P=0.505N	P=0.470N	P=0.158N	P=0.453N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Lymph Node, Mesenteric
Ectasia**

LESION RATES

OVERALL (a)	1/49 (2%)	0/48 (0%)	1/49 (2%)	2/50 (4%)
POLY-3 RATE (b)	1/39.70	0/44.43	1/47.78	2/49.24
POLY-3 PERCENT (g)	2.5%	0%	2.1%	4.1%
TERMINAL (d)	1/30 (3%)	0/38 (0%)	1/41 (2%)	1/43 (2%)
FIRST INCIDENCE	731 (T)	---	731 (T)	530

STATISTICAL TESTS

POLY 3	P=0.287	P=0.478N	P=0.717N	P=0.574
POLY 1.5	P=0.276	P=0.487N	P=0.733N	P=0.551
POLY 6	P=0.298	P=0.467N	P=0.701N	P=0.599
COCH-ARM / FISHERS	P=0.255	P=0.505N	P=0.753N	P=0.508
MAX-ISO-POLY-3	P=0.337	P=0.160N	P=0.451N	P=0.359

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Lymph Node, Mesenteric
Infiltration Cellular Mixed Cell**

LESION RATES

OVERALL (a)	1/49 (2%)	0/48 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/40.17	0/44.43	0/47.78	0/48.62
POLY-3 PERCENT (g)	2.5%	0%	0%	0%
TERMINAL (d)	0/30 (0%)	0/38 (0%)	0/41 (0%)	0/43 (0%)
FIRST INCIDENCE	592	---	---	---

STATISTICAL TESTS

POLY 3	P=0.327N	P=0.480N	P=0.466N	P=0.462N
POLY 1.5	P=0.318N	P=0.488N	P=0.477N	P=0.474N
POLY 6	P=0.338N	P=0.471N	P=0.454N	P=0.450N
COCH-ARM / FISHERS	P=0.303N	P=0.505N	P=0.500N	P=0.495N
MAX-ISO-POLY-3	P=0.123N	P=0.160N	P=0.158N	P=0.157N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Lymph Node, Mesenteric
Infiltration Cellular Plasma Cell**

LESION RATES

OVERALL (a)	0/49 (0%)	0/48 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/39.70	0/44.43	0/47.78	0/48.62
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/30 (0%)	0/38 (0%)	0/41 (0%)	0/43 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Lymph Node: Lumbar
Ectasia**

LESION RATES

OVERALL (a)	1/7 (14%)	2/7 (29%)	0/3 (0%)	0/2 (0%)
POLY-3 RATE (b)	1/5.91	2/6.31	0/2.61	0/2.00
POLY-3 PERCENT (g)	16.9%	31.7%	0%	0%
TERMINAL (d)	1/5 (20%)	2/5 (40%)	0/1 (0%)	0/2 (0%)
FIRST INCIDENCE	731 (T)	731 (T)	---	---

STATISTICAL TESTS

POLY 3	P=0.422N	P=0.525	P=0.661N	P=0.717N
POLY 1.5	P=0.423N	P=0.519	P=0.658N	P=0.724N
POLY 6	P=0.430N	P=0.527	P=0.674N	P=0.710N
COCH-ARM / FISHERS	P=0.435N	P=0.500	P=0.700N	P=0.778N
MAX-ISO-POLY-3	P=0.419N	P=0.292	P=0.288N	P=0.311N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Lymph Node: Lumbar
Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	2/7 (29%)	0/7 (0%)	0/3 (0%)	0/2 (0%)
POLY-3 RATE (b)	2/6.78	0/6.31	0/2.61	0/2.00
POLY-3 PERCENT (g)	29.5%	0%	0%	0%
TERMINAL (d)	1/5 (20%)	0/5 (0%)	0/1 (0%)	0/2 (0%)
FIRST INCIDENCE	367	---	---	---

STATISTICAL TESTS

POLY 3	P=0.249N	P=0.236N	P=0.464N	P=0.532N
POLY 1.5	P=0.239N	P=0.230N	P=0.450N	P=0.535N
POLY 6	P=0.266N	P=0.239N	P=0.489N	P=0.525N
COCH-ARM / FISHERS	P=0.227N	P=0.231N	P=0.467N	P=0.583N
MAX-ISO-POLY-3	P=0.272N	P=0.074N	P=0.227N	P=0.255N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Lymph Node: Renal
Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	2/7 (29%)	0/7 (0%)	0/3 (0%)	0/2 (0%)
POLY-3 RATE (b)	2/6.78	0/6.31	0/2.61	0/2.00
POLY-3 PERCENT (g)	29.5%	0%	0%	0%
TERMINAL (d)	1/5 (20%)	0/5 (0%)	0/1 (0%)	0/2 (0%)
FIRST INCIDENCE	367	---	---	---

STATISTICAL TESTS

POLY 3	P=0.249N	P=0.236N	P=0.464N	P=0.532N
POLY 1.5	P=0.239N	P=0.230N	P=0.450N	P=0.535N
POLY 6	P=0.266N	P=0.239N	P=0.489N	P=0.525N
COCH-ARM / FISHERS	P=0.227N	P=0.231N	P=0.467N	P=0.583N
MAX-ISO-POLY-3	P=0.272N	P=0.074N	P=0.227N	P=0.255N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

Mesentery: Fat Hemorrhage

LESION RATES

OVERALL (a)	0/16 (0%)	3/17 (18%)	1/15 (7%)	0/10 (0%)
POLY-3 RATE (b)	0/14.80	3/16.46	1/14.79	0/9.96
POLY-3 PERCENT (g)	0%	18.2%	6.8%	0%
TERMINAL (d)	0/11 (0%)	3/16 (19%)	1/13 (8%)	0/9 (0%)
FIRST INCIDENCE	---	731 (T)	731 (T)	---

STATISTICAL TESTS

POLY 3	P=0.465N	P=0.127	P=0.500	(e)
POLY 1.5	P=0.481N	P=0.123	P=0.494	(e)
POLY 6	P=0.439N	P=0.136	P=0.509	(e)
COCH-ARM / FISHERS	P=0.500N	P=0.125	P=0.484	(e)
MAX-ISO-POLY-3	P=0.313	P=0.045*	P=0.162	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Mesentery: Fat
Necrosis**

LESION RATES

OVERALL (a)	14/16 (88%)	14/17 (82%)	13/15 (87%)	10/10 (100%)
POLY-3 RATE (b)	14/15.79	14/17.00	13/15.00	10/10.00
POLY-3 PERCENT (g)	88.7%	82.4%	86.7%	100%
TERMINAL (d)	10/11 (91%)	13/16 (81%)	11/13 (85%)	9/9 (100%)
FIRST INCIDENCE	607	563	704	721

STATISTICAL TESTS

POLY 3	P=0.252	P=0.494N	P=0.646N	P=0.375
POLY 1.5	P=0.243	P=0.510N	P=0.660N	P=0.359
POLY 6	P=0.269	P=0.464N	P=0.621N	P=0.406
COCH-ARM / FISHERS	P=0.229	P=0.530N	P=0.675N	P=0.369
MAX-ISO-POLY-3	P=0.252	P=0.311N	P=0.433N	P=0.150

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Nose
Inflammation**

LESION RATES

OVERALL (a)	3/50 (6%)	28/50 (56%)	48/50 (96%)	46/49 (94%)
POLY-3 RATE (b)	3/40.77	28/45.49	48/49.44	46/48.38
POLY-3 PERCENT (g)	7.4%	61.6%	97.1%	95.1%
TERMINAL (d)	2/31 (7%)	26/38 (68%)	42/42 (100%)	41/43 (95%)
FIRST INCIDENCE	713	690	690	648

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Nose: Olfactory Epithelium
Atrophy**

LESION RATES

OVERALL (a)	1/50 (2%)	50/50 (100%)	50/50 (100%)	49/49 (100%)
POLY-3 RATE (b)	1/40.92	50/50.00	50/50.00	49/49.00
POLY-3 PERCENT (g)	2.4%	100%	100%	100%
TERMINAL (d)	0/31 (0%)	38/38 (100%)	42/42 (100%)	43/43 (100%)
FIRST INCIDENCE	674	298	653	530

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Nose: Olfactory Epithelium
Metaplasia Respiratory**

LESION RATES

OVERALL (a)	1/50 (2%)	49/50 (98%)	50/50 (100%)	49/49 (100%)
POLY-3 RATE (b)	1/40.70	49/49.07	50/50.00	49/49.00
POLY-3 PERCENT (g)	2.5%	99.9%	100%	100%
TERMINAL (d)	1/31 (3%)	38/38 (100%)	42/42 (100%)	43/43 (100%)
FIRST INCIDENCE	731 (T)	401	653	530

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Nose: Olfactory Epithelium, Glands
Hyperplasia**

LESION RATES

OVERALL (a)	17/50 (34%)	50/50 (100%)	50/50 (100%)	49/49 (100%)
POLY-3 RATE (b)	17/42.74	50/50.00	50/50.00	49/49.00
POLY-3 PERCENT (g)	39.8%	100%	100%	100%
TERMINAL (d)	12/31 (39%)	38/38 (100%)	42/42 (100%)	43/43 (100%)
FIRST INCIDENCE	519	298	653	530

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Ovary
Angiectasis**

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	2/50 (4%)	1/49 (2%)
POLY-3 RATE (b)	1/40.91	0/45.29	2/48.78	1/47.80
POLY-3 PERCENT (g)	2.4%	0%	4.1%	2.1%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	2/42 (5%)	1/43 (2%)
FIRST INCIDENCE	676	---	731 (T)	731 (T)

STATISTICAL TESTS

POLY 3	P=0.550	P=0.480N	P=0.561	P=0.724N
POLY 1.5	P=0.530	P=0.487N	P=0.540	P=0.739N
POLY 6	P=0.570	P=0.472N	P=0.581	P=0.708N
COCH-ARM / FISHERS	P=0.494	P=0.500N	P=0.500	P=0.747
MAX-ISO-POLY-3	P=0.459	P=0.158N	P=0.346	P=0.458N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Ovary
Cyst**

LESION RATES

OVERALL (a)	10/50 (20%)	11/50 (22%)	6/50 (12%)	11/49 (22%)
POLY-3 RATE (b)	10/42.24	11/46.42	6/48.78	11/47.84
POLY-3 PERCENT (g)	23.7%	23.7%	12.3%	23%
TERMINAL (d)	6/31 (19%)	8/38 (21%)	6/42 (14%)	10/43 (23%)
FIRST INCIDENCE	367	586	731 (T)	721

STATISTICAL TESTS

POLY 3	P=0.481N	P=0.597	P=0.126N	P=0.568N
POLY 1.5	P=0.517N	P=0.562	P=0.151N	P=0.577
POLY 6	P=0.446N	P=0.559N	P=0.106N	P=0.515N
COCH-ARM / FISHERS	P=0.503	P=0.500	P=0.207N	P=0.479
MAX-ISO-POLY-3	P=0.410N	P=0.498	P=0.092N	P=0.470N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Pituitary Gland: Pars Distalis
Hyperplasia**

LESION RATES

OVERALL (a)	9/49 (18%)	11/50 (22%)	10/50 (20%)	7/50 (14%)
POLY-3 RATE (b)	9/39.94	11/45.29	10/48.78	7/48.65
POLY-3 PERCENT (g)	22.5%	24.3%	20.5%	14.4%
TERMINAL (d)	8/30 (27%)	11/38 (29%)	10/42 (24%)	6/43 (14%)
FIRST INCIDENCE	666	731 (T)	731 (T)	723

STATISTICAL TESTS

POLY 3	P=0.145N	P=0.526	P=0.511N	P=0.240N
POLY 1.5	P=0.181N	P=0.489	P=0.570N	P=0.284N
POLY 6	P=0.114N	P=0.566	P=0.452N	P=0.197N
COCH-ARM / FISHERS	P=0.266N	P=0.421	P=0.520	P=0.376N
MAX-ISO-POLY-3	P=0.233N	P=0.427	P=0.415N	P=0.183N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Skin
Inflammation Chronic**

LESION RATES

OVERALL (a)	3/50 (6%)	3/50 (6%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	3/42.42	3/45.93	1/48.78	1/49.24
POLY-3 PERCENT (g)	7.1%	6.5%	2.1%	2%
TERMINAL (d)	0/31 (0%)	1/38 (3%)	1/42 (2%)	0/43 (0%)
FIRST INCIDENCE	514	639	731 (T)	530

STATISTICAL TESTS

POLY 3	P=0.137N	P=0.625N	P=0.258N	P=0.255N
POLY 1.5	P=0.146N	P=0.638N	P=0.273N	P=0.271N
POLY 6	P=0.129N	P=0.610N	P=0.244N	P=0.238N
COCH-ARM / FISHERS	P=0.165N	P=0.661N	P=0.309N	P=0.309N
MAX-ISO-POLY-3	P=0.220N	P=0.461N	P=0.138N	P=0.137N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Spleen
Hematopoietic Cell Proliferation**

LESION RATES

OVERALL (a)	5/50 (10%)	3/50 (6%)	6/50 (12%)	4/50 (8%)
POLY-3 RATE (b)	5/42.90	3/46.42	6/49.17	4/48.66
POLY-3 PERCENT (g)	11.7%	6.5%	12.2%	8.2%
TERMINAL (d)	1/31 (3%)	0/38 (0%)	4/42 (10%)	3/43 (7%)
FIRST INCIDENCE	367	563	653	721

STATISTICAL TESTS

POLY 3	P=0.465N	P=0.314N	P=0.594	P=0.422N
POLY 1.5	P=0.486N	P=0.329N	P=0.563	P=0.448N
POLY 6	P=0.444N	P=0.296N	P=0.624N	P=0.394N
COCH-ARM / FISHERS	P=0.533N	P=0.357N	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.485N	P=0.206N	P=0.469	P=0.303N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Spleen
Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	3/50 (6%)	0/50 (0%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	3/40.70	0/45.29	2/48.78	2/48.62
POLY-3 PERCENT (g)	7.4%	0%	4.1%	4.1%
TERMINAL (d)	3/31 (10%)	0/38 (0%)	2/42 (5%)	2/43 (5%)
FIRST INCIDENCE	731 (T)	---	731 (T)	731 (T)

STATISTICAL TESTS

POLY 3	P=0.552N	P=0.101N	P=0.419N	P=0.420N
POLY 1.5	P=0.559N	P=0.107N	P=0.446N	P=0.448N
POLY 6	P=0.545N	P=0.094N	P=0.390N	P=0.391N
COCH-ARM / FISHERS	P=0.577N	P=0.121N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.251N	P=0.038N*	P=0.272N	P=0.272N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Stomach, Forestomach
Hyperplasia**

LESION RATES

OVERALL (a)	2/50 (4%)	3/50 (6%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	2/40.94	3/45.50	0/48.78	2/48.62
POLY-3 PERCENT (g)	4.9%	6.6%	0%	4.1%
TERMINAL (d)	1/31 (3%)	2/38 (5%)	0/42 (0%)	2/43 (5%)
FIRST INCIDENCE	666	674	---	731 (T)

STATISTICAL TESTS

POLY 3	P=0.429N	P=0.548	P=0.201N	P=0.630N
POLY 1.5	P=0.443N	P=0.531	P=0.213N	P=0.652N
POLY 6	P=0.416N	P=0.566	P=0.190N	P=0.606N
COCH-ARM / FISHERS	P=0.474N	P=0.500	P=0.247N	P=0.691N
MAX-ISO-POLY-3	P=0.328N	P=0.373	P=0.075N	P=0.434N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Stomach, Forestomach
Inflammation**

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/40.94	0/45.29	0/48.78	0/48.62
POLY-3 PERCENT (g)	2.4%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/42 (0%)	0/43 (0%)
FIRST INCIDENCE	666	---	---	---

STATISTICAL TESTS

POLY 3	P=0.328N	P=0.480N	P=0.465N	P=0.466N
POLY 1.5	P=0.319N	P=0.487N	P=0.477N	P=0.478N
POLY 6	P=0.338N	P=0.473N	P=0.454N	P=0.454N
COCH-ARM / FISHERS	P=0.306N	P=0.500N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.123N	P=0.158N	P=0.158N	P=0.158N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Stomach, Forestomach
Ulcer**

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	1/41.34	2/45.50	1/48.88	1/48.66
POLY-3 PERCENT (g)	2.4%	4.4%	2.1%	2.1%
TERMINAL (d)	0/31 (0%)	1/38 (3%)	0/42 (0%)	0/43 (0%)
FIRST INCIDENCE	521	674	704	721

STATISTICAL TESTS

POLY 3	P=0.480N	P=0.533	P=0.722N	P=0.723N
POLY 1.5	P=0.497N	P=0.522	P=0.735N	P=0.736N
POLY 6	P=0.464N	P=0.547	P=0.707N	P=0.708N
COCH-ARM / FISHERS	P=0.531N	P=0.500	P=0.753N	P=0.753N
MAX-ISO-POLY-3	P=0.561N	P=0.317	P=0.455N	P=0.457N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Stomach, Glandular
Necrosis**

LESION RATES

OVERALL (a)	0/49 (0%)	0/49 (0%)	0/49 (0%)	0/49 (0%)
POLY-3 RATE (b)	0/40.49	0/44.33	0/47.89	0/47.80
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/42 (0%)	0/43 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Tooth
Malformation**

LESION RATES

OVERALL (a)	0/1 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
POLY-3 RATE (b)	0/1.00	0/0.00	0/0.00	0/0.00
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/1 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Urinary Bladder: Transitional Epithelium
Eosinophilic Granules Cytoplasmic**

LESION RATES

OVERALL (a)	0/49 (0%)	50/50 (100%)	49/49 (100%)	49/49 (100%)
POLY-3 RATE (b)	0/39.70	50/50.00	49/49.00	49/49.00
POLY-3 PERCENT (g)	0%	100%	100%	100%
TERMINAL (d)	0/30 (0%)	38/38 (100%)	42/42 (100%)	43/43 (100%)
FIRST INCIDENCE	---	298	656	530

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Uterus: Endometrium
Hyperplasia Cystic**

LESION RATES

OVERALL (a)	46/50 (92%)	50/50 (100%)	47/50 (94%)	48/50 (96%)
POLY-3 RATE (b)	46/48.93	50/50.00	47/49.61	48/49.96
POLY-3 PERCENT (g)	94%	100%	94.8%	96.1%
TERMINAL (d)	29/31 (94%)	38/38 (100%)	41/42 (98%)	42/43 (98%)
FIRST INCIDENCE	367	298	656	530

STATISTICAL TESTS

POLY 3	P=0.593	P=0.118	P=0.612	P=0.496
POLY 1.5	P=0.582	P=0.109	P=0.621	P=0.481
POLY 6	P=0.594	P=0.122	P=0.579	P=0.502
COCH-ARM / FISHERS	P=0.431	P=0.059	P=0.500	P=0.339
MAX-ISO-POLY-3	P=0.354	P=0.038*	P=0.434	P=0.319

LEGEND

- (a) Number of tumor-bearing animals/number of animals examined at site.
 - (b) Number of tumor-bearing animals/Poly-3 number
 - (d) Observed incidence at terminal kill.
 - (f) Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death.
 - (e) Value of Statistic cannot be computed.
 - (g) Poly-3 adjusted lifetime tumor incidence.
 - (I) Interim sacrifice
 - (T) Terminal sacrifice
 - # Tumor rates based on numbers of animals necropsied.
 - * To the right of any statistical result, indicates significance at ($P \leq 0.05$).
 - ** To the right of any statistical result, indicates significance at ($P \leq 0.01$).
 - N Indicates a negative trend for all tests
- Logistic regression is an alternative method for analyzing the incidence of non-fatal tumors.
The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

*** END OF REPORT ***